Citations

Clear

229 citation(s) found for "Chow, W".

Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe, Matthew M , Le-Rademacher, Jennifer G , Haffty, Bruce G , Hansen, Eric K , Wagner, Jamie L , Kong, Iwa , Whelan, Timothy J , Kour, Odum, Lee, Minji K , Ruddy, Kathryn J , Partridge, Ann H , Carey, Lisa A , Lustberg, Maryam , Chow, Selina , Stecklein, Shane Richard , Gaffney, David K , Khan, Atif J.

Mayo Clinic

Journal of Clinical Oncology | October 12, 2026 | Volume: 44 | Issue: 32 | Pages: 3128-3138

10.1200/jco-26-00474 | PMID 42863096 Get It

PURPOSE Patients with breast cancer requiring postmastectomy radiation therapy (PMRT) often desire breast reconstruction. Reconstructions can be adversely affected by PMRT, and fear of reconstruction complications has discouraged adoption of short-course radiation therapy used after lumpectomy. To fill the evidence gap, we conducted a noninferiority trial of hypofractionated versus conventional PMRT in patients undergoing breast reconstruction. The primary outcome was reconstruction complication rate, a composite of wound healing, readmission, capsular contracture, unplanned reoperation, and reconstruction failure. METHODS Women with unilateral invasive breast cancer with planned immediate or delayed reconstruction and PMRT were randomly assigned (1:1) to 50 Gy (25 fractions/5 weeks) or 42.56 Gy (16 fractions/3 weeks). This study was designed with a noninferiority margin of 10%, assuming a 2-year reconstruction complication rate of 25% with conventional PMRT. Randomization was stratified by immediate versus delayed and autologous versus implant-only reconstruction. RESULTS Between 2018 and 2021, 898 patients enrolled with a median follow-up of 3.9 years; 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, corresponding to an estimated difference of -2.1% (95% CI, -6.5 to 2.2). The complication rate was higher (regardless of arm) with implant-only versus autologous reconstruction (odds ratio = 1.65). There was no statistically significant difference in 36-month locoregional recurrence rates: 1.5% (95% CI, 0.7 to 3.2) with hypofractionated and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT. Acute and late toxicity rates were not statistically different. CONCLUSION A 16-fraction course of hypofractionated PMRT is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.
Low-frequency bipolar versus high-frequency monopolar cortical and subcortical motor mapping in craniotomies for brain tumors
Chow, William, Loron, Ali Gharibi , Keough, Michael B. , Malik, Noor, You, Hyo Bin , Do, B., Schwartz, J, Reilly, Charles, Michaelcheck, Charlotte E., Hoffman, Ernest M., Chow, William D, Do, Bobby, Schwartz, Jenna , Bauman, Megan M. J. , Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.1.jns251897 | PMID 42430806 Get It

OBJECTIVE Maximal safe resection of intra-axial brain tumors near the motor cortex is aided by intraoperative motor mapping. Here, the authors compared outcomes in patients undergoing either low-frequency bipolar stimulation (LFBS) or high-frequency monopolar stimulation (HFMS) for cortical and/or subcortical motor mapping during brain tumor resection. METHODS A retrospective analysis of patients undergoing an asleep craniotomy with motor mapping or an awake craniotomy with motor and speech mapping with a single surgeon was performed. Three cohorts were compared: 1) asleep LFBS (AsLFBS), 2) awake LFBS (AwLFBS; motor + speech mapping), and 3) asleep HFMS. HFMS mapping was not used for awake craniotomies. RESULTS A total of 284 patients who underwent 300 craniotomies with motor mapping were identified. No significant differences in permanent neurological deficits (p = 0.377) or extent of resection (EOR) of nonenhancing tumors (p = 0.453) were identified between LFBS or HFMS motor mapping cases. Both EOR (92.7% vs 83.5%, p = 0.035) and permanent neurological deficits (7.6% vs 3.3%) occurred more frequently in enhancing tumors with LFBS, although the latter was not statistically significant. HFMS was associated with higher rates of subcortical motor pathway identification (p = 0.001) and fewer total intraoperative seizures (p = 0.003) compared with LFBS. Previous resection (HR 0.46, p = 0.003) and a higher cortical threshold (HR 0.95, p = 0.023) were significantly associated with longer survival, while preoperative aphasia (HR 2.24, p = 0.022), hospital length of stay (HR 1.1, p = 0.005), an insular-based tumor (HR 3.5, p = 0.021), and a histological diagnosis of glioblastoma (HR 2.9, p = 0.001) were negative predictors. Interestingly, overall FLAIR EOR was significantly associated with a marginally decreased overall survival (HR 1.01, p = 0.011). CONCLUSIONS No significant differences in postoperative neurological deficits were found between LFBS and HFMS paradigms. HFMS may identify subcortical motor fibers more reliably while resulting in significantly fewer intraoperative seizures. Although LFBS was associated with greater EOR of contrast-enhancing tumors, it may also be associated with higher rates of postoperative deficits, perhaps reflecting less reliable identification of subcortical motor fibers.
Correcting spatial transcriptomics data affected by a prevalent transcript leakage problem across platforms, species, and tissues
Shi, Christina Huan , Zhai, Yibo, Chow, Savio Ho-Chit , Flores, Jesus, Kern, Colin , Adams, Peter D, Ren, Bing, Zhu, Quan, Carver, Chase M., Yip, Kevin Y , Carver, Chase Matthew , Teneche, Marcos G. , Ren, Bing , Schafer, Marissa , Wei, Yingying , Yip, Kevin Y.

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.13.732076 | PMID 42367830 Get It

Abstract Spatial transcriptomics has been widely applied to study the spatial distribution of cell types, cell states, and specific gene expression in tissue samples. However, we show that there is a prevalent transcript leakage problem in spatial transcriptomics data, where transcripts expressed by a cell diffuse to its neighborhood and are recurrently detected in the nearby cells. By analyzing published data sets, we show that this problem is general across data produced from different tissues and different species using different imaging-based and sequencing-based spatial transcriptomics platforms. It affects both upstream tasks such as expression quantification as well as downstream tasks such as cell-type annotation and detection of spatially-dependent gene expression. To tackle the transcript leakage problem, we propose a reference-free Bayesian model-based method, DeLeakage, which cleans up the data much more effectively than existing denoising methods. DeLeakage also improves cell-type annotation and avoids false detection of spatially dependent expression.
The future of oncology research: Replacing case report forms with mCODE-aligned electronic health record data for clinical trial data curation (Alliance).
Vetter, Christopher, Campbell, Nancy, Emamekhoo, Hamid, Chow, Selina, Elrahi, Cassandra, Commers, Winifred, Birgin, Alisha, Galanis, E., Piantadosi, Steven, Vetter, Christopher D. , Tevaarwerk, Amyé , Emamekhoo, Hamid , Elrahi, Cassandra

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e13661 Get It

e13661 Background: The process of data abstraction and curation represents a significant proportion of clinical trial costs, requiring up to $30,000 per patient depending on the data complexity. Research variables such as stage, performance status (PS), and cancer disease status are typically present in the electronic health record (EHR) in free text but require abstraction for research use. Structuring these real-world data (RWD) in an exportable format utilizing minimum common oncology data elements (mCODE) could reduce the need for abstraction and the potential for erroneous transcription that has been shown to be 5.51-7.72% in a meta-analysis. We assessed the feasibility, availability, and accuracy of RWD for use across Alliance for Clinical Trials in Oncology sites by comparing RWD to matched electronic case report form data (CRF data) at 2 sites where EHR-integrated tools collect structured RWD for all solid tumor patients. Methods: Stage, PS, and cancer disease status (CDS) were extracted from the EHR as RWD and from eCRFs for 100 patients enrolled in National Clinical Trials Network trials across multiple disease sites from 2022 through 2025. Data from baseline and day 1 of cycles 1-4 were compared (500 encounter timepoints). Results: Stage, PS, and CDS were available from RWD more often than CRFs (85 vs 70 / 100 patients, 436 vs 416 / 500 encounters, and 345 vs 83 / 500 encounters respectively). When stage was present in both (n = 58), there were 5 mismatches (8.6%). PS had 22 mismatches (4%) and CDS had 45 mismatches (11.4%). After correcting for differences in CRF vs RWD definitions, CDS mismatches dropped to 1.2% (n = 4). Discordance between RWD and CRF data was related to differences in the timepoint of data collection (e.g., systemic staging scans completed after the initial consult), CRF data obtained from other EHR notes (e.g., oncology research nurse notes containing PS), inherent discordance between RWD and CRF data choices (e.g., responding vs complete or partial response), and failure to update EHR data capture tool fields. RWD were available 21 days (median) before CRF data. Conclusions: Our results suggest that RWD captured directly within clinical notes match CRF data, are more often present, and are available sooner. RWD could serve as a data source for trials, decreasing the need for manual curation and cost. Although some discordance exists, overall rates are low and close to the published error rate for abstraction.
cfDNA WGS vs plasma proteomics for minimally invasive MRD assessment in multiple myeloma.
Abelman, Dor, Wong, Aimee, Eagles, Jenna , Shah, Saumil , Bruce, Jeff, Campos, Cecília Bonolo de , White, Darrell, Song, Kevin , Braggio, Esteban, Murugesan, Alli , Stewart, Keith, Reiman, Tony, Trudel, Suzanne, Abelman, Dor , Wong, Aimee, Bruce, Jeffrey, Pedersen, Stephanie , Scott, David S. , Chow, Signy , White, Darrell , Sandhu, Irwindeep , Braggio, Esteban , Trudel, Suzanne , Pugh, Trevor J.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7546-7546

10.1200/jco.2026.44.16_suppl.7546 Get It

7546 Background: MRD assessment informs relapse risk in MM but is typically bone marrow-based and invasive. We therefore compared two minimally invasive MRD assays: BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM). Methods: 71 longitudinal plasma samples (22 diagnosis, 49 follow-up) from 22 newly diagnosed MM patients across 8 Canadian sites (TFRIM4) had paired cfWGS and EasyM (Rapid Novor Inc). cfWGS MRD used patient-specific mutation lists from diagnostic BM WGS (Abelman et al., medRxiv 2025). EasyM used mass spectrometry to quantify residual M-protein from baseline. The primary endpoint was progression-free survival (PFS). Results: Among 22 MM patients (8 male, 14 female; median age at diagnosis 62 years), 8 progressed at a median follow-up of 52.6 months (range: 10-79 months). At 1-year maintenance (n = 18 available), cfWGS MRD+ (6/18) predicted inferior PFS (HR 20.12, 95% CI 2.23-181.60, p = 0.007). EasyM any-detect positivity was frequent (16/18, reflecting delayed clearance) and not prognostic (p = 0.99), with poor agreement vs cfWGS (44.4%, κ = 0.118). An exploratory EasyM clearance threshold of 0.93% (hypothesis-generating) classified 5/18 patients as MRD+ and stratified PFS (HR 8.78, 95% CI 1.55-49.82, p = 0.004), improving agreement with cfWGS (17/18, 94.4%, κ = 0.870). Progression clustered in cfWGS+/EasyM-high patients (EasyM >0.93%; 4/5; median 11.9 months post-collection [1.9–22.8]) and occurred once in cfWGS−/EasyM-low patients (1/12, 27.6 months). The only discordant case (cfWGS+/EasyM−) progressed 8.7 months after collection. Higher quantitative MRD burden was associated with inferior PFS (cfWGS: HR 2.92 per 1 SD, 95% CI 1.29-6.59, p = 0.01; EasyM: HR 5.48 per 1 SD, 95% CI 0.79-37.90, p = 0.085). At ~100 days post-autologous stem cell transplantation (ASCT; n = 16 available), EasyM was uniformly MRD+ (16/16) while cfWGS was MRD+ in 7/16 patients. Applying an EasyM clearance threshold (2.13%; 9 cleared vs 7 residual) improved agreement with cfWGS (14/16; 87.5%; κ = 0.746). Of two discordant cases, one cfWGS+/EasyM-cleared patient relapsed 38.6 months post-collection and one cfWGS−/EasyM-residual patient remained progression-free at last follow-up. At post-ASCT, both assays showed consistent but underpowered associations with PFS (cfWGS HR 6.32, 95% CI 0.70–56.76, p = 0.100; EasyM-clearance HR 2.36, 95% CI 0.39–14.18, p = 0.335). Across all post-treatment samples (n = 49), continuous cfWGS burden correlated with EasyM residual M-protein (rho = 0.535, p < 0.001). Conclusions: BM-informed cfWGS MRD strongly stratified PFS, whereas EasyM required a clearance definition due to near-universal early positivity. Concordant plasma burdens support complementary MRD information. Future work will validate these findings in larger cohorts and quantify the incremental value of combined cfWGS and proteomic MRD for early relapse prediction.
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology,
Rilland, Eddy D. Zandee van , Fayad, Laura M. , Link, Thomas M. , Davis, Kirkland W. , Wu, Jim S. , Chang, Eric Y. , Chow, Lawrence C. , Desai, Shaun C., Fritz, Jan, Gorbachova, Tetyana , Gray, Mingyang L., Gross, Joel A. , Ha, Patrick K., Halle, Tyler R. , Hall, M. Kennedy, Lee, Mark A. , Mann, Edana D. , Obey, Mitchel R. , Osgood, Greg M., Patel, Zara M. , Rendon, Juan M. , Sabbatini, Amber K. , Tannoury, Chadi , Yu, Joseph S. , Boutin, Robert D. , Zandee van Rilland, Eddy D , Brown, Ian P , Chang, Eric Y , Chow, Lawrence C , Gatz, J David , Garner, Hillary W , Gorbachova, Tetyana , Guermazi, Ali , Halle, Tyler R , Hanna, Tarek N , Kornblith, Aaron E , Lopez-Ben, Robert R , Mann, Edana D , Moore, Christopher L. , Obey, Mitchel R , Patel, Zara , Raja, Ali S , Rendon, Juan M , Sabbatini, Amber K , Tannoury, Chadi , Yu, Joseph S , Boutin, Robert D , Link, Thomas M , Desai, Shaun C. , Fritz, Jan , Garner, Hillary W. , Gray, Mingyang Liu , Hall, M. Kennedy , Osgood, Greg Michael

Mayo Clinic

Radiology | May 19, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252309 | PMID 42153836 Get It

Expert consensus recommendations from 21 academic centers were established for appropriate radiography utilization at 12 potentially low-yield anatomic sites through a multidisciplinary process endorsed by six major American medical societies.
Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase 2 trial (Alliance A171901)
Lee, Minji K. , Kour, Oudom, Satele, Daniel , Presley, Carolyn J. , Le-Rademacher, Jennifer, Ojelabi, Michael, Chow, Selina, Stinchcombe, Thomas E, Homan, Sherri , Finnes, Heidi D. , Waqar, Saiama, Jatoi, Aminah , Le‐Rademacher, Jennifer , Chow, Selina , Ojelabi, Michael Olayiwola , Le-Rademacher, Jennifer G , Ojelabi, Michael O , Presley, Carolyn J , Chow, Selina , Wong, Melisa L. , Stinchcombe, Thomas E. , Waqar, Saiama N

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag157 | PMID 42161344 Get It

Abstract Background Older adults remain underrepresented in prospective trials of immunotherapy for advanced lung cancer. To estimate pembrolizumab adverse events, we conducted a multicenter, nonrandomized, open-label phase 2 trial of oncologist-choice first-line pembrolizumab with or without chemotherapy for older adults with advanced lung adenocarcinoma. Methods Alliance for Clinical Trials in Oncology A171901 enrolled patients aged 70 years and older with stage IV or recurrent lung adenocarcinoma starting oncologist’s choice of first-line pembrolizumab with or without carboplatin and pemetrexed. The primary endpoint was the proportion of patients experiencing a solicited grade 3 or greater adverse event within 6 months. Secondary endpoints included overall survival, quality of life, and association of a geriatric assessment toxicity risk score with severe adverse events. Results Among 95 evaluable patients, 43 (45.3%) received pembrolizumab and 52 (54.7%) received pembrolizumab plus chemotherapy. Median age was 77 years (range = 70-92 years); 11.6% had an E Performance Status of 2 or higher. During 6 months of treatment, 25.6% (95% CI = 13.5% to 41.2%) experienced a solicited grade 3 or greater adverse event in the monotherapy group and 42.3% (95% CI = 28.7% to 56.8%) in the combination group. Median overall survival was 16.4 months (95% CI = 10.1 to not estimable) with monotherapy and 29.9 months (95% CI = 16.4 to not estimable) with combination therapy. Quality of life worsened during treatment. The geriatric assessment toxicity risk score was not associated with severe adverse events with pembrolizumab with or without chemotherapy. Conclusions Older adults with advanced lung adenocarcinoma receiving pembrolizumab with or without chemotherapy had comparable adverse event rates to those in prior registration trials that excluded medically frail patients. These findings can inform shared decision making and support inclusion of older adults in future trials. Clinical Trial NCT04533451 (https://clinicaltrials.gov/study/NCT04533451)
Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain
Zahrieh, David, Satele, Daniel , Haamankuli, Hiboombe , Le‐Rademacher, Jennifer , Lee, M E, Liu, Heshan, Diaz-Cobo, Julian, Shen, Shu‐En , Chow, S F, Lustberg, Maryam, Ruddy, Kathryn J. , Smith, Elizabeth , Lee, Minji K. , Zahrieh, David , Chow, Selina , Zahrieh, David , Le-Rademacher, Jennifer G , Lee, Minji K , Shen, Shu-En , Chow, Selina , Ruddy, Kathryn J , Lavoie Smith, Ellen M , Zahrieh, David , Wang, Xin Shelley , Lustberg, Maryam B.

Mayo Clinic

Cancers | May 11, 2026 | Volume: 18 | Issue: 10 | Pages: 1514

10.3390/cancers18101514 | PMID 42192875 Get It

Background/Objectives. Decades of research have failed to uncover effective approaches to prevent chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of neurotoxic chemotherapy. Increased interest in placebo response as a potentially under-recognized confounder in CIPN trials was recently sparked by the results of a multisite NCI-funded phase II-III CIPN prevention study of duloxetine, a promising serotonin–norepinephrine reuptake inhibitor that enhances pain-inhibitory mechanisms within the central nervous system. Study findings revealed high and nearly equivalent response rates in three randomized treatment groups—little to no CIPN was reported by 65.2%, 66.0%, and 68.0% of study participants who received duloxetine 30 mg, 60 mg, or placebo treatment, respectively. Methods. We performed a meta-analysis of placebo response rates from seven randomized, double-blinded, placebo-controlled trials conducted over the past 20 years and comprising 191 placebo participants that were specifically testing interventions for oxaliplatin- and paclitaxel-induced peripheral neuropathy and that serially collected patient responses on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Neuropathy questionnaire. Additionally, we sought to identify trial- and patient-specific factors that predicted higher placebo response rates from a participant-level pooled analysis. Results. The placebo response rate was 10.0% [95% CI: 5.8%, 16.6%] when response was defined more conservatively as patients reporting no neuropathy at all. When the placebo response was defined more broadly based on patients reporting no or a little neuropathy, the placebo response rate was higher (39.6% [95% CI: 27.4%, 53.2%]). Male participants, receipt of oxaliplatin, and a 2:1 randomization ratio favoring the intervention arm were individually associated with a higher placebo response. Conclusions. High placebo response rates can threaten scientific progress toward identifying effective treatments for cancer treatment-associated side effects, like CIPN. Careful attention to study design factors, participant eligibility, and patient and research staff expectations may help to minimize placebo response rates in future CIPN intervention studies.
Differential awakening of the sciatic nerve: illustrative case
Chow, William, Texakalidis, Pavlos , Jones, Felipe J S , Spinner, Robert J, Jones, Felipe J.S. , Chow, William D, Spinner, Robert J , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | May 11, 2026 | Volume: 11 | Issue: 18 | Pages: No page available

10.3171/case251028 | PMID 42081837 Get It

BACKGROUND Differential awakening is a well-known, yet poorly understood phenomenon seen in patients with intracranial pathologies. Because acute postoperative neurological decline has many potentially reversible causes, distinguishing differential awakening from other etiologies is critical. To the authors’ knowledge, differential awakening has not been reported following peripheral nerve procedures. OBSERVATIONS A 40-year-old man presented with a 1.5-year history of painful bilateral cervical and right lumbosacral radiculoplexus neuropathy recently associated with bilateral facial and vestibulocochlear neuropathy. He had not responded to treatment trials. A sciatic nerve lesion in the sciatic notch was identified on imaging and an open biopsy of the posterior femoral cutaneous nerve was pursued. Immediately after emergence from anesthesia, he demonstrated a complete inability to dorsiflex or plantar flex the right foot, despite minimal intraoperative manipulation of the sciatic nerve. Over the ensuing hour, motor function progressively returned to baseline. The transient postoperative motor deficit was attributed to differential awakening of the sciatic nerve. Pathological analysis confirmed high-grade B-cell lymphoma. LESSONS Differential awakening may be an underrecognized cause of transient neurological worsening during emergence from anesthesia following peripheral nerve surgery. Further investigation is needed to clarify the underlying mechanisms and define its incidence and risk factors. https://thejns.org/doi/10.3171/CASE251028